Characterization of Airway Mucus in Bronchiectasis Patients and Healthy Controls
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03125174|
Recruitment Status : Completed
First Posted : April 24, 2017
Last Update Posted : July 24, 2017
|Condition or disease|
In this study the investigators will investigate the mucus properties in individuals with idiopathic bronchiectasis and healthy individuals without a history of lung disease. In order to understand how mucus is abnormal in disease conditions, the investigators need to understand the mucus biochemical and biophysical properties in healthy individuals. In this study the investigators will prospectively recruit patients with bronchiectasis and healthy individuals from the community to provide airway sputum samples. In these samples the investigators will measure an array of mucus properties. This will help our understanding of the mucus-obstructive lung diseases and facilitate the development of appropriate and effective disease prevention strategies.
A key question is whether mucus is hyper-concentrated and has abnormal biophysical properties in individuals with mucus-obstructive lung disease. To answer this question, the investigators need to understand the properties of the mucus in individuals with idiopathic bronchiectasis and no history of lung disease. This study will allow us to collect airway mucus (sputum) from individuals with bronchiectasis and healthy individuals with no history of lung disease.
|Study Type :||Observational|
|Actual Enrollment :||30 participants|
|Official Title:||Characterization of Airway Mucus in Bronchiectasis Patients and Healthy Controls|
|Actual Study Start Date :||March 10, 2017|
|Actual Primary Completion Date :||June 27, 2017|
|Actual Study Completion Date :||June 27, 2017|
healthy individuals with no history of lung disease
individuals with a diagnoses of bronchiectasis
- Mucus concentration (% solids) [ Time Frame: 6 months ]The percentage of solid content of sputum (an index of hydration) will be calculated my measuring the wet to dry weight ratio using a microbalance (mean percent solids ± standard deviation).
- Biophysical properties of mucus by rheology [ Time Frame: 6 months ]The rheological properties of the sputum will be assayed by macro-rheology (cone and plate) and microbead rheology. Macro-rheology provides measures of the viscosity (median log viscosity in Pascal (range)) and elasticity (median log elasticity in Pascal (range) of the sputum. Microbead rheology is performed by analyzing the diffusive motion of embedded 1μm tracer particles (6). The primary outcome measure from microbead rheology will be the mean square displacement MSD(Mean squared displacement) (median MSD cm2 s-1 (range)).
- Mucin composition by mass spectroscopy [ Time Frame: 6 months ]We will use mass spectroscopy to determine the relative abundance of the two major polymeric mucin proteins, MUC5B(Mucin type 5B)and MUC5AC(Mucin type 5AC), which are responsible for the viscoelastic properties of mucus.
- Sputum extracellular nucleotide analysis [ Time Frame: 6 months ]Sputum adenosine and adenine nucleotides will be ethenoderivatized and measured by HPLC(High performance liquid chromatography) analysis (7) (median nucleotide concentration in μg/ml (range)).
- Osmotic Pressure [ Time Frame: 6 months ]The osmotic pressure of the mucus will be assessed by placing an aliquot of mucus onto an osmometer with a 10kDa (10 kilodaltons) molecular weight polyethersulfone membrane (Millipore) separating the test chamber and reference chamber filled with PBS (phosphate-buffered saline) (mean osmotic pressure in Pascal ± standard deviation).
- Total mucin concentration [ Time Frame: 6 months ]Mucins will be quantitated using sepharose CL2B(Cross-linked derivative of Sepharose 2B) UPLC(Ultra performance liquid chromatography) coupled to an Optilab interference refractometer with a filter at 680 nm and parallel flow chambers for solvent and the solution (mean mucin concentration (μg/ml) ± standard deviation) (4). With this approach, we will ensure that the solute is at full Donnan equilibrium with the solution within the context of gel chromatography, which creates an accurate equilibration of solute and solvent. This procedure also separates the mucins from contaminating proteins, allowing the mucins to be isolated for biochemical studies. DNAse can be added if significant DNA is present.
- polymeric DNA concentration [ Time Frame: 6 months ]The quantification of free DNA will be performed using the DNA Quant-iT PicoGreen assay (Molecular Probes, Inc., Eugene, OR, USA), which utilizes an ultra-sensitive fluorescent nucleic acid stain for quantitating double-stranded DNA (median log DNA concentration (μg/ml) (range)).
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03125174
|United States, North Carolina|
|Center for Environmental Medicine Asthma and Lung Biology|
|Chapel Hill, North Carolina, United States, 27599|
|Marsico Research Institure at Meadowmont|
|Chapel Hill, North Carolina, United States, 27599|
|Study Chair:||Richard Boucher, MD||University of North Carolina, Chapel Hill|
|Principal Investigator:||Kathryn Ramsey||University of North Carolina, Chapel Hill|